KRAS and cancer: In addition, our RNA liquid-biopsy technology enables non-invasive, systemic monitoring of protein-coding and repeat-derived cell-free RNA responses to targeted therapies, such as KRAS inhibitors36, which induce treated cancer cells to preferentially release TE-derived cell-free RNAs in extracellular vesicles9.